Bio-Techne (TECH) | Stock Overview & Key Data
Bio-Techne Performance Comparison
Stock Range
Today's Range
Low: $49.15
High: $50.84
on August 7, 2025
52 Week Range
Low: $46.01
High: $80.95
on April 21, 2025
on September 19, 2024
All-Time High: $135.96 on September 20, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$7.9B
EPS
0.83
P/E Ratio (TTM)
60.87
Forward P/E
23.07
P/B Ratio
3.92
PEG Ratio
23.07
Div. Yield
0.64%
ROE
6.53%
Beta
1.381
Debt to Equity
20.99
Financial Highlights
Profitability
Gross Margin
67.86%
Operating Margin
14.10%
Profit Margin
10.89%
Returns and Earnings
Return on Assets (TTM)
5.24%
Return on Equity (TTM)
6.53%
EBITDA
$321.2M
Net Income (TTM)
$131.6M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$7.64
Quarterly Revenue Growth (YoY)
4.20%
Quarterly Earnings Growth (YoY)
-54.00%
Dividend Information
Last 12-Month Dividend
$0.32
Current Dividend Yield
0.64%
3-Year Average Dividend Yield
0.11%
3-Year Average Annual Dividend
$0.32
3-Year Total Dividends
$0.96
Ex-Dividend Date
May 19, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Bio-Techne TECH | 7.92B Mid-cap | -8.37% | -2.70% | 2.87% | -31.12% | -29.84% | -30.51% | -47.46% | -23.58% |
| Vertex VRTX | 121.28B Large-cap | -17.78% | -18.24% | -13.61% | -19.96% | -7.43% | -17.68% | 30.94% | 44.28% |
| Regeneron REGN | 60.39B Large-cap | 2.63% | 4.03% | -0.20% | -21.15% | -21.73% | -50.93% | -11.70% | -9.38% |
| Exelixis EXEL | 10.15B Large-cap | 3.23% | -15.33% | 1.58% | 11.68% | 10.16% | 38.64% | 91.94% | 70.11% |
| BridgeBio Pharma BBIO | 8.68B Mid-cap | -2.79% | 5.63% | 28.28% | 44.27% | 62.94% | 88.09% | 296.12% | 61.06% |
| Blueprint Medicines BPMC | 8.37B Mid-cap | 0.12% | 1.05% | 53.79% | 15.63% | 48.46% | 12.60% | 149.54% | 73.38% |
Ownership & Short Interest
Insider Ownership
1.06%
Institutional Ownership
105.63%
Shares Short
8M
Short Ratio
2.72
Short % of Shares Outstanding
5.52%
Average 10-Day Volume
2M
Average 90-Day Volume
3M
Bio-Techne Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Bio-Techne would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is TECH's 52-week high and low?
- In the last 52 weeks, Bio-Techne reached a high of $80.95 (on September 19, 2024) and a low of $46.01 (on April 21, 2025).
- What is the market cap and P/E ratio for TECH?
- Curious about Bio-Techne's size and valuation? Its market capitalization stands at 7.92B. When it comes to valuation, the P/E ratio (trailing twelve months) is 60.87, and the forward P/E (looking ahead) is 23.07.
- Does TECH pay dividends? If so, what's the yield?
- Yes, Bio-Techne is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.64%, and the company has paid an average of $0.32 per share annually over the past 3 years.
- Who are Bio-Techne's main competitors or similar companies to consider before investing?
When looking at Bio-Techne, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX121.28B Healthcare Biotechnology -17.68% 30.94% Regeneron
REGN60.39B Healthcare Biotechnology -50.93% -11.70% Exelixis
EXEL10.15B Healthcare Biotechnology 38.64% 91.94% BridgeBio Pharma
BBIO8.68B Healthcare Biotechnology 88.09% 296.12% Blueprint Medicines
BPMC8.37B Healthcare Biotechnology 12.60% 149.54% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Bio-Techne Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Bio-Techne's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 6.53%, the Debt to Equity ratio from the most recent quarter is 20.99, and its Gross Profit Margin stands at 67.86%.
- What is the recent revenue and earnings growth for TECH?
- Looking at Bio-Techne's growth, its revenue over the trailing twelve months (TTM) was $1B. Compared to the same quarter last year (YoY), quarterly revenue grew by 4.20%, and quarterly earnings saw a YoY growth of -54.00%.
- How much of TECH stock is held by insiders and institutions?
- Wondering who owns Bio-Techne stock? Company insiders (like executives and directors) hold about 1.06% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 105.63%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.